{"id":"NCT04172441","sponsor":"Zealand Pharma","briefTitle":"Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism","officialTitle":"A Randomized Trial in 2 Parts: Double-Blind, Placebo-Controlled, Crossover Part 1 and Open-label Part 2, Evaluating the Efficacy and Safety of Dasiglucagon for the Treatment of Children With Congenital Hyperinsulinism","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2020-06-19","primaryCompletion":"2022-02-17","completion":"2022-03-07","firstPosted":"2019-11-21","resultsPosted":"2025-03-14","lastUpdate":"2025-03-14"},"enrollment":12,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Congenital Hyperinsulinism"],"interventions":[{"type":"DRUG","name":"dasiglucagon","otherNames":["ZP4207"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"dasiglucagon first then placebo","type":"EXPERIMENTAL"},{"label":"placebo first then dasiglucagon","type":"EXPERIMENTAL"}],"summary":"The objective of the trial is to evaluate the efficacy of dasiglucagon in reducing glucose requirements in children with persistent congenital hyperinsulinism (CHI) requiring continuous intravenous (IV) glucose administration to prevent/manage hypoglycemia.","primaryOutcome":{"measure":"Mean Intravenous Glucose Infusion Rate","timeFrame":"Hours 36-48 after initiation of trial drug (Part 1)","effectByArm":[{"arm":"Dasiglucagon","deltaMin":4.33,"sd":4.922},{"arm":"Placebo","deltaMin":9.51,"sd":5.655}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0037"}]},"eligibility":{"minAge":"7 Days","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":10},"locations":{"siteCount":6,"countries":["United States","Germany","Israel","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":12},"commonTop":["Vomiting","Aspartate Aminotransferase Increased","Rash Papular","Anaemia","Constipation"]}}